The Fight against Cancer with Oncotarget

Many dread the mention of cancer. It is said to be one of the top killer illness all over the world. Referencing a recent statistic, there will be an increasing 16 million estimated cases of detection in 2017, not forgetting the worrisome number of deaths. If we were to mitigate these cases, sensitization is where everyone ought to commence. Talking of public awareness in addition to finding out new, improved ways of curbing the epidemic, no better reputed, reputable, a reliable journal has done better in addressing this issue than the Oncotarget. Oncotarget is a global peer-reviewed journal, which establishes its mission on the basis of the pathology of all known cancers. Incepted in 2010, Oncotarget is published by Impact Journal and is conforming member of the set, predetermined Principles of the Committee on Publication Ethics, (COPE).

COPE is an entity comprised up of top publishers in the world is charged with the responsibility of ensuring that the publication ethics are adhered to by all the publications featuring in the peer review. Additionally, the body acts as editors’ advisor on matters relating to the handling of cases of publication and research misconduct and flaws.In the recent past, Oncotarget has been gaining in popularity which is attributable to its timely, insightful, reliable and constructive reviews which help its adept team of researchers in deepening their research on this deadly epidemic. The journal helps make known to the public potential targets, applicable treatment procedures, and protocols in addition to helping cancer patients live proper lives with the condition.

Readers of the journal have access to the latest therapies available currently in addition to evidence to support the fact that they are effective. In addition, the journal helps individuals to better accept themselves and the condition they are in, thus ameliorating the quality of their life. Medical practitioners are among other critical beneficiaries of the Oncotarget journal. Besides Oncology, the journal also allows papers on several other topics including; Cell Biology, Cardiology, Neuroscience, Cardiology, Pharmacology and Metabolism among other related disciplines. The journal benefits from an adept editorial bar comprising of Cancer Research’s former editor in chief, Carlo M. Croce and a Nobel Prize winner, Andrew Schally. Since its establishment, the journal has been benefiting from an able board with four of its members having won the Breakthrough Prize.

Groupon founder Eric Lefkofsky sees opportunity in oncology’s disarray

When Eric Lefkofsky, co-founder of volume discount giant Groupon, got the news that his wife was suffering from advanced breast cancer, he was understandably distraught. But over the next few months of going in and out of oncology offices around Chicago, he became even more worried, not by the state of his wife’s disease, which her oncology team was, by that time, highly confident would beat, but by the state of oncology itself.

Specifically, Lefkofsky was aghast to realize that oncology experts, at some of Chicago’s most prestigious medical institutions, had less real-time access to data and analytics than many truck drivers. This led Lefkofsky to begin studying the problem on his own. Eventually, he came to the conclusion that there was massive room for improvement in the way that oncologists are fed data. And the analytic tools that were available to them were both crude and weak.

Lefkofsky eventually founded Tempus, an oncological analytics company dedicated to teasing out the crucial patterns in the vast reams of data that are potentially available to oncologists and other medical professionals. Once of the largest sources of untapped and unparsed data is the human genome itself. The use of genomic sequencing has exploded over the last 15 years, with the price of sequencing an average human genome dropping by a factor of more than 20,000 times. In 2003, the first human genome was sequenced at a cost of over $100,000,000. Today, a person’s genome can be totally sequenced for just $5,000. Lefkofsky predicts that figure will drop to just a few hundred dollars in the coming decades, as computer capacity advances and new techniques become known.

Lefkofsky is working at Tempus to create a system that can act as a sort of on-demand meta-study platform, conducting real-time, sophisticated cancer analysis that will put into the hands of oncologists the necessary relationships between patient characteristics and treatment options to enable them to create a totally customized treatment regimen.

Rather than all patients suffering from a form of cancer receiving a one-size-fits-all treatment, a highly granular approach will be taken, with no two patients getting exactly the same combination of drugs, course and duration.

About Eric Lefkofsky: